Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
671 Phase 1 trial of human chimeric antigen receptor modified T cells (huCART-meso) administered in combination with oncolytic virus VCN-01 in patients with pancreatic and ovarian cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
